Stock Ticker

  • Loading stock data...

Amgen, Inc. (NASDAQ:AMGN) Migraine Treatment Drug Passes Phase 2 Trials

In a breakthrough in migraine treatment, the Phase 2 results of the clinical trials of AMG 334 drug by Amgen, Inc. (NASDAQ:AMGN) has been successful. Competing with the existing migraine drugs, the monthly rates of migraine attacks were comparably less when using this medication. According to the company, the AMG 334 drug lowered the chance […]